Pulmonary alveolar proteinosis – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Pulmonary alveolar proteinosis – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Pulmonary alveolar proteinosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pulmonary alveolar proteinosis: Overview
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterized by alveolar accumulation of surfactant-derived lipoproteinaceous material. This accumulation blocks air from entering alveoli and oxygen from passing through into the blood, which results in a feeling of breathlessness (dyspnea). Depending on the aetiology three main categories of PAP have been defined: auto-immune (previously named primary or idiopathic), secondary and genetic. Genetic PAP is seen especially in children, and radio-clinical presentation depends on the mutated gene. Auto-immune alveolar proteinosis is the most frequent form of PAP, representing 90% of cases. Patients with PAP are at an increased risk of developing an opportunistic infection.
Symptoms
The symptoms of Pulmonary alveolar proteinosis include:
Diagnosis of PAP is initiated by computed tomography (CT) scan and confirmed by staining of bronchoalveolar lavage fluid (BALF). PAP diagnosis rarely requires lung biopsy. Autoimmune PAP can be identified by very sensitive and specific blood tests that identify the presence or absence of an increased level of GM-CSF autoantibody. Hereditary PAP can be diagnosed by a series of blood tests. The genetic risk factors for hereditary PAP and congenital PAP can be identified by genetic testing.
Treatment
The standard treatment for PAP is symptomatic whole lung lavage. Therapy for PAP varies depending upon what disease is present, disease severity, and the age of the patient. Treatment of congenital PAP is generally supportive. Lung transplantation can be used in infants and children with congenital PAP caused by genetic mutations and in patients who develop significant lung fibrosis. Some novel therapies targeting alveolar macrophages (recombinant GM-CSF therapy) or anti-GM-CSF antibodies (rituximab and plasmapheresis) are under investigation.
Pulmonary alveolar proteinosis Emerging Drugs Chapters
This segment of the Pulmonary alveolar proteinosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary alveolar proteinosis Emerging Drugs
Further product details are provided in the report
Pulmonary alveolar proteinosis: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary alveolar proteinosis drugs segregated based on following parameters that define the scope of the report, such as:
Pulmonary alveolar proteinosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, preclinical and discovery stage. It also analyses Pulmonary alveolar proteinosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary alveolar proteinosis drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pulmonary alveolar proteinosis – Pipeline Insight, 2020,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Pulmonary alveolar proteinosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pulmonary alveolar proteinosis: Overview
Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterized by alveolar accumulation of surfactant-derived lipoproteinaceous material. This accumulation blocks air from entering alveoli and oxygen from passing through into the blood, which results in a feeling of breathlessness (dyspnea). Depending on the aetiology three main categories of PAP have been defined: auto-immune (previously named primary or idiopathic), secondary and genetic. Genetic PAP is seen especially in children, and radio-clinical presentation depends on the mutated gene. Auto-immune alveolar proteinosis is the most frequent form of PAP, representing 90% of cases. Patients with PAP are at an increased risk of developing an opportunistic infection.
Symptoms
The symptoms of Pulmonary alveolar proteinosis include:
- Cyanosis
- Chest pain or tightness
- Shortness of breath, also called dyspnea
- Fever
- Weight loss
- Cough (sometimes, but not always)
- Low levels of oxygen in the blood
- Nail clubbing (abnormal growth of toenails or fingernails)
- Fatigue
Diagnosis of PAP is initiated by computed tomography (CT) scan and confirmed by staining of bronchoalveolar lavage fluid (BALF). PAP diagnosis rarely requires lung biopsy. Autoimmune PAP can be identified by very sensitive and specific blood tests that identify the presence or absence of an increased level of GM-CSF autoantibody. Hereditary PAP can be diagnosed by a series of blood tests. The genetic risk factors for hereditary PAP and congenital PAP can be identified by genetic testing.
Treatment
The standard treatment for PAP is symptomatic whole lung lavage. Therapy for PAP varies depending upon what disease is present, disease severity, and the age of the patient. Treatment of congenital PAP is generally supportive. Lung transplantation can be used in infants and children with congenital PAP caused by genetic mutations and in patients who develop significant lung fibrosis. Some novel therapies targeting alveolar macrophages (recombinant GM-CSF therapy) or anti-GM-CSF antibodies (rituximab and plasmapheresis) are under investigation.
Pulmonary alveolar proteinosis Emerging Drugs Chapters
This segment of the Pulmonary alveolar proteinosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pulmonary alveolar proteinosis Emerging Drugs
- Molgradex: Savara
- Sargramostim: Bayer HealthCare Pharmaceuticals
Further product details are provided in the report
Pulmonary alveolar proteinosis: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary alveolar proteinosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pulmonary alveolar proteinosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Pulmonary alveolar proteinosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, preclinical and discovery stage. It also analyses Pulmonary alveolar proteinosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary alveolar proteinosis drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary alveolar proteinosis R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary alveolar proteinosis.
- On December 30, 2019, Savara announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.
- Pulmonary alveolar proteinosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pulmonary alveolar proteinosis drugs?
- How many Pulmonary alveolar proteinosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary alveolar proteinosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary alveolar proteinosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pulmonary alveolar proteinosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Savara
- Black Tie Medical
- Sanofi Genzyme
- Bayer HealthCare Pharmaceuticals
- Molgradex
- Cellular stromal vascular fraction (cSVF)
- Sargramostim
Introduction
Executive Summary
Pulmonary alveolar proteinosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary alveolar proteinosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pulmonary alveolar proteinosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pulmonary alveolar proteinosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Molgradex: Savara
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Sargramostim: Bayer HealthCare Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Pulmonary alveolar proteinosis Key Companies
Pulmonary alveolar proteinosis Key Products
Pulmonary alveolar proteinosis- Unmet Needs
Pulmonary alveolar proteinosis- Market Drivers and Barriers
Pulmonary alveolar proteinosis- Future Perspectives and Conclusion
Pulmonary alveolar proteinosis Analyst Views
Pulmonary alveolar proteinosis Key Companies
Appendix
Executive Summary
Pulmonary alveolar proteinosis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary alveolar proteinosis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pulmonary alveolar proteinosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pulmonary alveolar proteinosis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Molgradex: Savara
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Sargramostim: Bayer HealthCare Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Pulmonary alveolar proteinosis Key Companies
Pulmonary alveolar proteinosis Key Products
Pulmonary alveolar proteinosis- Unmet Needs
Pulmonary alveolar proteinosis- Market Drivers and Barriers
Pulmonary alveolar proteinosis- Future Perspectives and Conclusion
Pulmonary alveolar proteinosis Analyst Views
Pulmonary alveolar proteinosis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Pulmonary alveolar proteinosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Pulmonary alveolar proteinosis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Pulmonary alveolar proteinosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Pulmonary alveolar proteinosis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
